as of 05-05-2026 3:55pm EST
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Upcoming Earnings Alert:
Get ready for potential market movements as Oragenics Inc. (OGEN) prepares to release earnings report on 11 May 2026.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | LAKEWOOD RANCH |
| Market Cap: | 2.7M | IPO Year: | 2010 |
| Target Price: | N/A | AVG Volume (30 days): | 45.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.56 | EPS Growth: | -185.00 |
| 52 Week Low/High: | $0.11 - $9.16 | Next Earning Date: | 05-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.14 | Index: | N/A |
| Free Cash Flow: | -9373906.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See how OGEN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.